We are inviting views from industry, patient organisations and other stakeholders to input into a joint industry/government Medicines Investment and Commercial Environment Review process. The review is taking a collaborative, open, sprint-based approach, bringing together government and industry to explore bold, practical ideas which could be piloted to strengthen the UK medicines commercial environment, support life sciences investment and economic growth, and improve patient outcomes in line with the government's objectives in the Life Sciences Sector Plan. Overall, we are seeking to gather suggestions for potential pilotable ideas which could be used to inform future policy positions.
As mentioned, the review will operate in sprints, these are short time-boxed periods where stakeholders will focus on delivering specific objectives and actionable goals. The sprints will cover ideas to strengthen UK competitiveness, inward investment, economic growth, and patient benefits; potential pilots or future policies, which could improve patient access to and uptake of innovative medicines; and how these ideas could be delivered and measured in practice. The kinds of levers that are in scope concern the operation of the UK's commercial environment, covering three linked areas: i) the pricing of individual medicines/vaccines, ii) overall spending and market size, and iii) the breadth and speed of uptake of new medicines/vaccines in the health service.
We are asking for your views on the range of outcomes that the Review will aim to deliver, and as per the agreement with the US, suggestions for potential pilots or proof-of-concept approaches and the measures of success that should be used to assess impact for patients, the NHS, the economy and the UK’s wider life sciences ambitions. Some of these outcomes may already be captured in the OLS' Life Sciences Competitiveness Indicators, but others may warrant further work in order to fully develop.
Your responses will be shared confidentially with government and industry representatives taking part in the review, to inform the ideation phase. If you have given permission to be contacted, we may contact you to see if you would be willing to share further information with the sprint taskforce.
Thank you for sharing your views as part of this process.